In this regard, small molecule inhibitors of AurA and HDAC6 have been tested in clinical trials for treatment of cancer and neurodegenerative disease [44,45] and could serve as the basis for a novel class of anti-chlamydial antibiotics. Here, AURKA is linked to cancer.